Incretin hormones: Their role in health and disease

By M. Nauck, J. Meier. Diabetes, obesity and metabolism, 2018

781 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Glucagon-like peptide 1 (GLP-1) (2019, background): “Greater insulinotropic action of oral glucose relative to its peripheral administration was demonstrated for both normal weight and obese individuals [63] and henceforth became known as the incretin effect [64,65].”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “39,40,446 Notably, GLP-1RAs exhibit pronounced ef ﬁ cacy in optimizing blood lipid pro ﬁ les by effectively suppressing chylomicron secretion in the intestine, thereby mitigating the occurrence of postprandial hyperlipidemia.”
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept (2018, background): “GIP is responsible for the majority of the insulinotropic incretin effect in man [14,16] and has important additional functions that are distinct from GLP-1.”